Chinese Journal of Nuclear Medicine and Molecular Imaging 2019;39(11):641-646
doi:10.3760/cma.j.issn.2095-2848.2019.11.001
Predictive value of 18F-FDG PET conventional parameters and radiomics features for invasive breast cancer patients with uncertain HER2 expression by immunohistochemistry
Yufan ZHANG 1 ; Jianjing LIU ; Xiaofeng LI ; Wengui XU
Affiliations
Keywords
Breast neoplasms; Receptor, epidermal growth factor; Immunohistochemistry; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose; Radiomics
Country
China
Language
Chinese
Abstract
Objective:To explore the predictive value of 18F-fluorodeoxyglucose (FDG) PET conventional parameters and radiomics features for human epidermal growth factor receptor 2 (HER2) expression which was uncertain by immunohistochemistry (IHC) detection in invasive breast cancer.
Methods:From April 2012 to December 2017, 76 patients (all were females, age: (50.8±10.9) years) with invasive breast cancer and with uncertain HER2 expression by IHC in Tianjin Medical University Cancer Institute and Hospital were enrolled retrospectively. The 18F-FDG PET/CT images before treatment were reviewed and the expression of HER2 were confirmed by fluorescence in situ hybridization (FISH). The tumor lesions were manually outlined, and the radiomics features from PET images were extracted. Wilcoxon test was used to determine whether there was difference in PET conventional metabolic parameters (maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG)) and radiomics features between HER2-negative and HER2-positive groups. The receiver operating characteristic (ROC) curve analysis was used to compare the predictive efficacy of PET radiomics features for HER2 expression.
Results:There were 41 HER2-positive patients and 35 HER2-negative patients. No significant differences in PET conventional metabolic parameters between different HER2 expression groups were observed (
Conclusions:PET radiomics features can effectively identify HER2 expression in patients with invasive breast cancer to some extent, and the contrast may be the best. Conventional metabolic parameters have limited predictive value.
备案号: 11010502037788, 京ICP备10218182号-8)